Celgene bags CAR-T player Juno in $9B buyout as biotech M&A suddenly explodes
The buyout buzz was accurate.
Celgene $CELG has struck a deal to buy Juno Therapeutics $JUNO for $87 a share, or about $9 billion …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
